Policy · 117th Congress
House report questions FDA’s approval of Alzheimer’s drug
A decision on accelerated approval is due by Jan. 6, and the company is simultaneously submitting data for full approval based on results from a Phase 3 trial.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.
4 results for "6"
Policy · 117th Congress
Biden ponders marijuana moves as states forge ahead
The Biden administration’s Oct. 6 announcement that it would revisit that classification comes after previous, yearslong reviews of marijuana’s categorization fell flat, and experts are split on
Policy · 117th Congress
Medicare demo emerges as coverage option for Alzheimer’s drug
Alzheimer’s afflicts more than 6 million Americans, and is the sixth-leading cause of death in the United States.
Policy · 116th Congress
Five more states voting this fall on legalizing marijuana
New Approach Montana, the group behind the two ballot initiatives, told the Missoula Current it plans to spend $3 million to $6 million in total on the campaign.